文摘
摘要目的:检查之间的相关性在活的有机体内正电子发射断层扫描(PET)成像与18 f-pm-pbb3 (18 f-florzolotau)和后期神经病理发现病人进行性核上的麻痹(PSP)。
背景:没有报告证明紧PET-pathology non-Alzheimer-type同一个人在神经退行性疾病,包括PSP,特点是聚合four-repeatτ亚型。18 f-florzolotau PET探测器允许高对比度成像的老年痴呆症和non-Alzheimerτ病态无论同种型的作品,而这对量化示踪剂的效用的丰富τ存款生活情况下仍有待验证。
病人:一个65岁的男性PSP理查森综合症的临床诊断经历了11 c-pib淀粉样蛋白和18 f-florzolotauτPET扫描前一年尸体解剖。临床、神经影像学、神经病理结果在这种情况下,简要总结了其他神经元(K Tagai, et al . 2021年)。
图像分析:标准摄入值比(SUVR)图像生成从PET图像平均18 f-florzolotau注射后90 - 110分钟。参考区域决定使用一个优化参考组织方法(K Tagai等人medRxiv DOI:https://doi.org/10.1101/2022.02.13.22270135)。
神经病理分析:定量分析(τ)负担进行了使用一个anti-phosphorylatedτ抗体(AT8)。基于阈值的二值化方法用于确定意味着AT-8-positive面积(%面积τ负担)。
结果:18 f-florzolotau宠物显示增强radiosignals脑干、丘脑核,和基底神经节,和PSP-characteristicτ存款,包括神经原纤维缠结球形簇绒星形胶质细胞和螺旋机构,主要是在这些领域被神经病理化验证实。地区之间有密切的相关性radioprobe SUVR和%面积τ负担(r年代= 0.63,p< 0.0001)。淀粉样宠物被视觉阅读负面。
结论:18 f-florzolotau宠物措施反映了丰富的τ在PSP病态。
披露:Endo博士已经收到个人薪酬在500 - 4999美元的范围作为顾问APRINOIA疗法。Endo博士已经收到个人补偿的范围0 - 499美元的服务在演讲人AbbVie Inc . .Endo博士的机构已收到从jsp KAKENHI 21 k15705研究支持。荒木博士没有披露。武田博士没有披露。Takado博士没有披露。Tagai博士没有披露。松岗博士没有披露。塞其博士没有披露。Takahata博士没有披露。 Dr. Sahara has nothing to disclose. Hitoshi Shinotoh has nothing to disclose. Mr. Kawamura has nothing to disclose. Dr. Zhang has nothing to disclose. Dr. Honda has nothing to disclose. Prof. SHIMADA has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint. Prof. SHIMADA has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for eli lilly. Prof. SHIMADA has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda Pharmaceutical . Prof. SHIMADA has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Prof. SHIMADA has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Nihon Medi-Physics. Prof. SHIMADA has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Prof. SHIMADA has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for FUJIFILM Toyama Chemical. Prof. SHIMADA has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sunplanet . Prof. SHIMADA has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for NIPPON CHEMIPHAR. Prof. SHIMADA has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sumitomo Pharma. Prof. SHIMADA has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for GE Healthcare. Prof. SHIMADA has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for CHUGAI PHARMACEUTICAL. Prof. SHIMADA has received intellectual property interests from a discovery or technology relating to health care. Prof. SHIMADA has received publishing royalties from a publication relating to health care. Prof. SHIMADA has received publishing royalties from a publication relating to health care. Prof. SHIMADA has received publishing royalties from a publication relating to health care. The institution of Dr. Higuchi has received research support from APRINOIA Therapeutics.
